HSP90B1 and Hepatic failure: Given that circulating gp96 exits predominantly in patients with CHB and ACLF but not in healthy individuals, we believe that inhibition or depletion of circulating and intrahepatic extracellular gp96 may provide an effective strategy for the treatment of liver hyperactivation and liver failure.